Basic Info

Global Pharma Solutions (GPS): Experienced professionals accelerating medicine registrations globally.

GPS is a global regulatory and product development consulting firm with experts in both the US and Australia. We have over 22 years’ experience in developing and registering hundreds of products including small molecules, biologics and medical devices and 11 years’ experience with cell and gene therapies, particularly liaising with the FDA.

We guide biotech companies through complex development pathways, ensuring a clear route to market approval.

Through our partner CROs, we also offer support with clinical operations.

Why work with us

We are keen to connect at Bio Korea to discuss how we can support your clinical development, regulatory strategies and overall development objectives.

Each of our experts has more than 20 years' experience in developing and registering medicines and devices globally. We have supported several hundred development programs in many indications and have close to 100% approval success with global regulatory agencies.

In addition, with operations in both the US an Australia we are uniquely positioned to lend our global expertise to guide your program from preclinical, to clinical and final registration, using our valuable knowledge and wisdom, which has been proven to could save our clients significant amounts of time and money.

Having conducted your early clinical trials in Australia, our experts can help you open an IND in the US and potentially gain accelerated pathways and designations to expedite your program. This can also increase the value of your asset for a potential early exit.

There is no substitute for a knowledgeble team guiding you. Experience matters.....

Clients (7)

Mesoblast

Mesoblast Limited (ASX:MSB; Nasdaq:MESO) is a global leader in developing allogeneic cellular medicines for inflammatory diseases Mesoblast Limited is a world leader in the development of bi... read more

Emyria Limited

Emyria Limited accelerates drug development and clinical care by integrating patients, clinicians, researchers, and innovators to address unmet needs in neuroscience and mental health throug... read more

EnGeneIC

EnGeneIC develops targeted cancer therapies using their innovative EDV™ nanocell platform, achieving FDA 'Fast Track' designation for their pancreatic cancer treatment. read more

IQVIA

IQVIA Holdings, provides advanced analytics, technology solutions, and clinical research services to life sciences organizations, aiming to enhance healthcare delivery and expedite access to... read more

Brochure

Company focus

Services

Therapeutics
Vaccines
Vaccines
Industry Service Provider
Company Type (Public/Private)
Private

Industries

Biotechnology
Medical Devices
Pharmaceuticals

Projects or Case studies (2)

First MSC therapy approved by US FDA for pediatric acute GVHD

January 2019 - December 2024

GPS provided support with numerous FDA meetings leading up to BLA submission to FDA. GPS contributed to writing the dossier for submission

US FDA Advisory Committee

August 2020 - August 2020

US FDA advisory committee meeting for a first in class stem cell therapy. GPS provided support in: - Prepared CMC briefing - Prepared ‘response’ slides for all predicted CMC related questions - Provided appropriate response slides to the presenters during Q&A sessions. Outcome: Panel voted 9:1 in favour of approval.

Contacts

Marg Jenkins Avatar

Marg Jenkins